Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Ani Pharmaceuticals (ANIP) Depreciation Expense (2016 - 2020)

Ani Pharmaceuticals (ANIP) has disclosed Depreciation Expense for 9 consecutive years, with $1.3 million as the latest value for Q4 2020.

  • Quarterly Depreciation Expense rose 8.33% to $1.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2020, up 6.52% year-over-year, with the annual reading at $8.9 million for FY2025, 20.27% up from the prior year.
  • Depreciation Expense hit $1.3 million in Q4 2020 for Ani Pharmaceuticals, up from $1.2 million in the prior quarter.
  • In the past five years, Depreciation Expense ranged from a high of $1.3 million in Q4 2020 to a low of $200000.0 in Q1 2016.
  • Historically, Depreciation Expense has averaged $680000.0 across 5 years, with a median of $500000.0 in 2018.
  • Biggest five-year swings in Depreciation Expense: changed 0.0% in 2016 and later soared 300.0% in 2019.
  • Year by year, Depreciation Expense stood at $200000.0 in 2016, then skyrocketed by 50.0% to $300000.0 in 2017, then surged by 166.67% to $800000.0 in 2018, then skyrocketed by 50.0% to $1.2 million in 2019, then rose by 8.33% to $1.3 million in 2020.
  • Business Quant data shows Depreciation Expense for ANIP at $1.3 million in Q4 2020, $1.2 million in Q3 2020, and $1.2 million in Q2 2020.